← All trials
NCT04530656
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 28, 2020
- Primary completion
- Oct 28, 2020
- Completion date
- Aug 28, 2021
- First posted
- Aug 28, 2020
- Last posted
- Sep 1, 2020
- Enrollment
- 168
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaOverall official - principal investigator
- Sichuan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.